Compass Rose Asset Management LP Buys 1,650,000 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Compass Rose Asset Management LP raised its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 366.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,100,000 shares of the company's stock after buying an additional 1,650,000 shares during the period. Bausch Health Companies makes up approximately 6.9% of Compass Rose Asset Management LP's portfolio, making the stock its 6th largest position. Compass Rose Asset Management LP owned 0.58% of Bausch Health Companies worth $16,926,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Bausch Health Companies by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock valued at $94,460,000 after buying an additional 145,078 shares during the period. Franklin Resources Inc. boosted its position in Bausch Health Companies by 1.1% in the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock valued at $42,855,000 after buying an additional 56,446 shares during the period. Maple Rock Capital Partners Inc. boosted its position in Bausch Health Companies by 156.7% in the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after buying an additional 3,235,100 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after buying an additional 1,510,445 shares during the period. Finally, SG Americas Securities LLC boosted its position in Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after buying an additional 1,263,706 shares during the period. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Companies Price Performance

Shares of BHC traded up $0.29 during midday trading on Monday, reaching $4.88. The stock had a trading volume of 2,373,489 shares, compared to its average volume of 2,629,770. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85. The company's fifty day simple moving average is $5.79 and its two-hundred day simple moving average is $7.09. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -40.62, a PEG ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. On average, sell-side analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Finally, StockNews.com lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.